The Effect of FOsamprenavir/Ritonavir on the Pharmacokinetics of a Single-dose of the Antipsychotic Agent olanZApine (FORZA).

Trial Profile

The Effect of FOsamprenavir/Ritonavir on the Pharmacokinetics of a Single-dose of the Antipsychotic Agent olanZApine (FORZA).

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Fosamprenavir; Olanzapine; Ritonavir
  • Indications HIV infections; Schizophrenia
  • Focus Pharmacokinetics
  • Acronyms FORZA
  • Most Recent Events

    • 07 Jan 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 07 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jul 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top